| 1 |
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis |
|
|
| Niki Katsiki,Richard Ofori-Asenso,Ele Ferrannini,Mohsen Mazidi |
|
| Diabetes, Obesity and Metabolism. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout |
|
|
| T. S. Panevin,M. S. Eliseev,M. V. Shestakova,E. L. Nasonov |
|
| Terapevticheskii arkhiv. 2020; 92(5): 110 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Euglycemic diabetic ketoacidosis |
|
|
| Leonid Barski,Tamar Eshkoli,Evgenia Brandstaetter,Alan Jotkowitz |
|
| European Journal of Internal Medicine. 2019; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence |
|
|
| Niki Katsiki,George Dimitriadis,George Hahalis,Nikolaos Papanas,Nikolaos Tentolouris,Filippos Triposkiadis,Vasilios Tsimihodimos,Costas Tsioufis,Dimitri P. Mikhailidis,Christos Mantzoros |
|
| Metabolism. 2019; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Sodium–glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice |
|
|
| Shinji Tanaka,Yuki Sugiura,Hisako Saito,Mai Sugahara,Yoshiki Higashijima,Junna Yamaguchi,Reiko Inagi,Makoto Suematsu,Masaomi Nangaku,Tetsuhiro Tanaka |
|
| Kidney International. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet? |
|
|
| Sanjay Kalra,Jubbin Jacob,ManashP Baruah |
|
| Indian Journal of Endocrinology and Metabolism. 2018; 22(1): 164 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives |
|
|
| Hongyu Qiu,Aleksandra Novikov,Volker Vallon |
|
| Diabetes/Metabolism Research and Reviews. 2017; : e2886 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus |
|
|
| Hala Ahmadieh,Sami Azar |
|
| Diabetes Technology & Therapeutics. 2017; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy |
|
|
| D Dutta,S Kalra,M Sharma |
|
| Journal of Postgraduate Medicine. 2017; 63(2): 114 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES ON CANAGLIFLOZIN AND DEXAMETHASONE |
|
|
| Lisa D. Alexander,Catherine Yu |
|
| AACE Clinical Case Reports. 2017; 3(4): e331 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal |
|
|
| Vishal Gupta,William Canovatchel,BN Lokesh,Ravi Santani,Nishant Garodia |
|
| Indian Journal of Endocrinology and Metabolism. 2017; 21(6): 909 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 12 |
Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement |
|
|
| Sanjay Kalra,Sujoy Ghosh,AH Aamir,Md. Tofail Ahmed,MohammodFeroz Amin,Sarita Bajaj,ManashP Baruah,Uditha Bulugahapitiya,AK Das,Mimi Giri,Sonali Gunatilake,SaeedA Mahar,Md. Faruque Pathan,NazmulKabir Qureshi,SAbbas Raza,Rakesh Sahay,Santosh Shakya,Dina Shreshta,Noel Somasundaram,Manilka Sumanatilleke,AG Unnikrishnan,AchiniMadushani Wijesinghe |
|
| Indian Journal of Endocrinology and Metabolism. 2017; 21(1): 210 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 13 |
Dapagliflozin for the treatment of type 1 diabetes mellitus |
|
|
| Kalliopi Pafili,Efstratios Maltezos,Nikolaos Papanas |
|
| Expert Opinion on Investigational Drugs. 2017; 26(7): 873 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 14 |
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs |
|
|
| Sanjay Kalra,Yashdeep Gupta |
|
| Diabetes Therapy. 2016; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 15 |
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment |
|
|
| Heidi Storgaard,Jonatan I. Bagger,Filip K. Knop,Tina Vilsbøll,Jørgen Rungby |
|
| Basic & Clinical Pharmacology & Toxicology. 2016; 118(2): 168 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 16 |
Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review |
|
|
| AwadheshKumar Singh,Ritu Singh |
|
| Indian Journal of Endocrinology and Metabolism. 2016; 20(1): 32 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 17 |
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect |
|
|
| Sanjay Kalra,Arpit Jain,Jignesh Ved,AG Unnikrishnan |
|
| Indian Journal of Endocrinology and Metabolism. 2016; 20(5): 725 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 18 |
Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight |
|
|
| AwadheshKumar Singh |
|
| Indian Journal of Endocrinology and Metabolism. 2015; 19(6): 722 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
